文献速递脊柱关节炎

抑制CCL20治疗强直性脊柱炎炎症的研究

CCL20 inhibition for treating inflammation in ankylosing spondylitis.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

本研究探讨抑制C-C基序趋化因子配体20(CCL20)治疗强直性脊柱炎(AS)炎症的有效性。AS患者滑液单个核细胞中Th17细胞和CCL20表达细胞高于外周血,AS滑液中CCL20水平显著高于骨关节炎患者。CCL20抑制剂可减少Th17细胞比例和迁移,并在SKG小鼠模型中显著减轻关节炎症。

要点

  • AS患者滑液单个核细胞中Th17细胞及CCL20表达细胞高于外周血。
  • AS患者滑液中CCL20水平显著高于骨关节炎患者。
  • CCL20抑制剂在SKG小鼠模型中显著减轻关节炎症。

核心结论

  • 本研究证实CCL20在AS中的关键作用,并提示靶向抑制CCL20可能成为AS治疗的新方法。

研究设计与样本

  • 研究采集健康个体和AS患者的外周血单个核细胞(PBMC)及滑液单个核细胞(SFMC),用流式细胞术分析产炎性细胞因子的细胞,用ELISA测定CCL20水平,用Trans-well迁移实验验证CCL20对Th17细胞迁移的影响,并用SKG小鼠模型评估CCL20抑制的体内疗效。

主要发现

  • AS患者SFMC中Th17细胞和CCL20表达细胞的存在高于其PBMC。
  • AS患者滑液中CCL20水平显著高于OA患者。
  • AS患者PBMC暴露于CCL20后Th17细胞百分比增加,而AS患者SFMC经CCL20抑制剂处理后Th17细胞百分比降低。
  • Th17细胞迁移受CCL20影响,该效应被CCL20抑制剂抵消。
  • 在SKG小鼠模型中,使用CCL20抑制剂显著减轻关节炎症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Th17 cells are known to play a significant role in AS. C-C motif chemokine ligand 20 (CCL20) binds to C-C chemokine receptor 6 (CCR6) on Th17 cells, promoting their migration to inflammation sites. The aim of this research is to examine the effectiveness of CCL20 inhibition in treating inflammation in AS. METHODS: Mononuclear cells from peripheral blood (PBMC) and SF (SFMC) were collected from healthy individuals and AS. Flow cytometry was used to analyse cells producing inflammatory cytokines. CCL20 levels were determined using ELISA. The impact of CCL20 on Th17 cell migration was verified using a Trans-well migration assay. The in vivo efficacy of CCL20 inhibition was evaluated using an SKG mouse model. RESULTS: The presence of Th17 cells and CCL20 expressing cells was higher in SFMCs from AS patients compared with their PBMCs. The CCL20 level in AS SF was significantly higher than in OA patients. The percentage of Th17 cells in PBMCs from AS patients increased when exposed to CCL20, whereas the percentage of Th17 cells in SFMCs from AS patients decreased when treated with CCL20 inhibitor. The migration of Th17 cells was found to be influenced by CCL20, and this effect was counteracted by the CCL20 inhibitor. In the SKG mouse model, the use of CCL20 inhibitor significantly reduced joint inflammation. CONCLUSION: This research validates the critical role of CCL20 in AS and suggests that targeting CCL20 inhibition could serve as a novel therapeutic approach for AS treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Won EJ, Kim HJ, Lee YJ, et al. CCL20 inhibition for treating inflammation in ankylosing spondylitis. Rheumatology (Oxford). 2023. PMID: 37279731. doi:10.1093/rheumatology/kead268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。